hotspot -WSS

hotspot

author：entertainment 2025-08-11 11:42:22 - browse：7

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Argenx readies a blockbuster opportunity with drug for autoimmune disease

WSS

Virtual Event: March of the Biosimilars

Why rehabilitation engineers need to center patients in their research

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Melinda French Gates resigns from Gates Foundation

Health AI adoption puts security, privacy startups on investors' radar

Health care needs a new profession: neuroimaging counseling

hotspot

hotspot

entertainment

Guidelines to prevent youth baseball injuries need more muscle

After traumatic brain injury, life support decisions can use more time

Sports medicine is finally prioritizing gender equality

MultiPlan and major insurers sued for alleged medical price

Cancer drug shortages should be causing more outrage

Methadone treatment changes are coming. Do they go far enough?

Alkermes shareholders re

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Virginia high school admissions case could be legal follow

Cancer researcher Catriona Jamieson is sending tumors into space

knowledge

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

More tobacco lobbyists active in statehouses

UnitedHealth financials solid despite Change Healthcare cyberattack

MassMutual is introducing free genetic testing for members

Cancer researcher Catriona Jamieson is sending tumors into space

Cancer researcher Catriona Jamieson is sending tumors into space

focus

knowledge

hotspot

focus